Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Zhang T, Na JH, Li S, Chen Z, Zhang G, Pang S, et al. Functional impact of cancer patient-associated Bcl-xL mutations. MedComm (Beijing). 2020;1(3):328-337.

Dillard A, DeSimone RA, Hsu Y-, Ma L, Vasovic L, Racine-Brzostek S, et al. Flat line in the blood bank: code H (hyperfibrinolysis)? Transfusion. 2020;60(9):1894-1896.

Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun. 2020;11(1):1987.

Patel SS, Weinberg OK. Diagnostic workup of acute leukemias of ambiguous lineage. Am J Hematol. 2020;95(6):718-722.

Cushing MM, Haas T, Karkouti K, Callum J. Which is the preferred blood product for fibrinogen replacement in the bleeding patient with acquired hypofibrinogenemia-cryoprecipitate or fibrinogen concentrate? Transfusion. 2020;60 Suppl 3:S17-S23.

Petroni G, Formenti SC, Chen-Kiang S, Galluzzi L. Immunomodulation by anticancer cell cycle inhibitors. Nat Rev Immunol. 2020;20(11):669-679.

Arnold A, Imada EL, M Zhang L, Edward DP, Marchionni L, Rodriguez FJ. Differential gene methylation and expression of HOX transcription factor family in orbitofacial neurofibroma. Acta Neuropathol Commun. 2020;8(1):62.

Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, et al. Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2020;585(7826):E20.

Mustafa S, VandenBussche CJ, Ali SZ, Siddiqui MT, Wakely PE. Cytomorphologic findings of low-grade fibromyxoid sarcoma. J Am Soc Cytopathol. 2020;9(3):191-201.

Sadick N, Magro C. Response to Letter to the Editor. J Am Acad Dermatol. 2020.